June 2, 2026 – Productivity, Pixels, and Payrolls: Decoding Today’s AI‑Driven Market Tape -( $ALAB $AVGO $HPE $INTG $MCD $MRVL $MTWO $NOK $SOAR $TSLA Rise!)

US equities traded just below record highs on Tuesday, June 2, 2026, as an AI-fueled tech rally ran into profit-taking and persistent geopolitical and macro uncertainty ahead of a key jobs data week. AI infrastructure names, semis, and select consumer and casino stocks stayed bid, while mega-cap issuance, crypto weakness, and rate path ambiguity kept broader risk appetite in check.

Headline market moves

US stocks hovered near all-time highs after a powerful two-month run driven largely by AI and chip names. The S&P 500 and Nasdaq traded only fractionally above Monday’s close but higher nevertheless, while the Dow added .45% to close at 51,307.79.

AI, chips, and infrastructure: still the core narrative

The AI complex remains the primary driver of equity risk, with flows clustering in semis, data-center infrastructure, and select software/security names.

• Hewlett Packard Enterprise (HPE) closed at $56.15, +19.47% after posting a record quarter anchored by AI data-center demand, with cloud and AI revenue up roughly 23% year over year and guidance moving higher.
• Marvell Technology (MRVL) jumped 32.52% to $290.79 rallying after Nvidia CEO Jensen Huang publicly framed the company as a potential “next $1 trillion firm,” highlighting its role in AI networking and accelerator infrastructure.
• Broadcom (AVGO), $481.57, +4,70%) gained mid‑single digits as investors extrapolated incremental AI chip demand from Alphabet’s massive capex plans and Huang’s broader bullishness on the AI hardware stack.

At the platform level, AI capex is now center stage: Alphabet’s stock slipped roughly 3.81% after announcing plans to raise around 80 billion dollars of equity to fund AI computing infrastructure, a reminder that the capex supercycle also carries dilution and margin risks for existing shareholders. Macro strategists increasingly view AI investment as both a growth driver and a shock absorber—supporting productivity and capex even as other sectors slow—yet also as a potential bubble if earnings delivery fails to match valuation inflation.

Macro and rates: jobs week and the Fed’s next move

This week’s macro calendar is all about labor and the Fed’s reaction function, with investors parsing every data point for signals on growth, inflation, and policy timing.

• U.S. employers posted higher then expected 7.6M job vacancies in April, the Labor Department reported Tuesday, up from 6.9M in March, while economists had forecast just 6.8M openings.
• Friday’s nonfarm payrolls print looms large after May’s jobs growth of roughly 115,000 and a 4.3% unemployment rate kept the labor market looking resilient but not overheating.
• Inflation remains sticky at about 3.8% headline and 2.8% core, leaving the Fed comfortable staying on hold at its June 17 meeting—futures imply better than a 99% probability of no move.

On the rates side, the 10‑year Treasury yield sits in the mid‑4.4% area, off recent highs but still well above pre‑AI boom levels. Interestingly, correlations between front-end yields and the S&P 500 have turned historically negative, suggesting equities are currently willing to look through modest rate back‑ups as long as AI earnings momentum remains intact.

Geopolitics, oil, and crypto risk sentiment

Geopolitics continues to shape the tail distribution for risk assets, particularly via oil and energy sentiment.

• Crude Oil prices remain elevated around the $93/bbl, +1.45% today after a recent spike tied to tensions in Lebanon and complications around US‑Iran talks.
• Energy equities have lagged broader indices over the past month despite higher crude, reflecting skepticism over the durability of the current price band and the market’s preference for AI‑linked growth stories.

Digital assets, by contrast, have been a pressure point rather than a risk-on confirmation signal. Bitcoin futures fell roughly 3–4% to just under 70,000 after a major crypto proxy (Strategy/MSTR) disclosed late‑May bitcoin sales, reinforcing the notion that some institutional players are de‑risking into strength.

This stock-level churn is reflected in volatility metrics: while the headline VIX sits in the mid‑teens—signaling calm at the index level—the Cboe VIXEQ and dispersion indices are elevated, implying heightened single-stock volatility and low correlation between constituents. For active managers and options traders, this environment favors stock-picking and targeted volatility strategies over broad beta exposure.

Macro narrative and investor positioning takeaways

From a narrative-finance perspective, today’s tape is about tension between “AI as secular growth engine” and “macro and geopolitical gravity.”

• AI-driven capex and productivity optimism are sustaining index-level strength, especially as tech, semis, and AI infrastructure dominate market-cap weighting and earnings revisions..
• At the same time, elevated inflation, a cautious Fed, persistent conflict risk in the Middle East, and energy price volatility continue to cap the multiple investors are willing to pay outside of the AI complex.

Positioning remains skewed toward growth and AI proxies, leaving the market vulnerable to any disappointment in AI earnings, regulatory shocks, or a meaningful upside surprise in wage or inflation data. For allocators, this argues for:

• Stress-testing portfolios against both a reversal in AI sentiment and a higher-for-longer rates scenario.
• Watching labor data and the June Fed meeting for any shift in rhetoric around the balance between growth risks and inflation persistence.
• Paying attention to single-stock volatility and dispersion when structuring options overlays or hedges, given the gap between calm index vol and choppy stock-level moves.

VP Watchlist Updates

Below is an update‑style snapshot on the VP Watchlist names for the week, focused on recent catalysts, positioning, and narrative rather than precise price moves.

Astera Labs, Inc. (ALAB, $355.76, +11.14%)

Astera Labs, Inc. (Nasdaq: ALAB), a leader in semiconductor-based connectivity solutions for rack-scale AI infrastructure, recently (May 5) announced preliminary financial results for the first quarter of fiscal year of 2026, ended March 31, 2026. they highlighted the following: Record quarterly revenue of $308.4 million, up 14% QoQ and up 93% year-over-year, Market-leading PCIe 6 AI fabric and signal conditioning portfolio delivered strong growth during Q1, & Now shipping newly announced Scorpio™ X-Series 320-lane AI Fabric switch and expanded Scorpio P-Series PCIe 6 switch family supporting 32 to 320 lanes.

Amwell® (AMWL, $8.50)

Amwell® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, highlighted (May 18) results from an independently led, National Institute of Mental Health-funded randomized trial published in Nature Human Behaviour examining SilverCloud® by Amwell®, the company’s digital behavioral health solution.

Amwell announced (May 5) financial results for the first quarter ended Mar. 31, 2026. “Entering 2026, Amwell’s main focus was to consolidate our platform to fulfill the unmet needs of our Payer and Provider customers. The Technology-Enabled Care infrastructure we have developed to fill that gap in the market continues to gain traction as customers recognize its clear advantages: lower costs, better outcomes, stronger market share and an increased level of control and agility. Our platform is performing well and built to leverage the latest AI-powered innovations, positioning it as essential infrastructure for tech-enabled care delivery,” said Dr. Ido Schoenberg, Chairman and CEO of Amwell. “We are seeing powerful validation of the platform with significant pipeline growth and a number of meaningful renewals. With this momentum and the favorable regulatory tailwinds, Amwell is well-positioned for continued strong execution this year and to reach our goal of positive cash flow from operations in the fourth quarter.”

Eupraxia Pharmaceuticals (EPRX, $6.65)

Eupraxia Pharmaceuticals Inc. (EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, announced (May 5) the first Eosinophilic Esophagitis Endoscopic Reference Score (EREFS) data from its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis (“EoE”). These data were also presented at the ongoing Digestive Disease Week (“DDW”) conference in Chicago. “The EREFS is an important, validated visual index of severity of EoE disease in the esophagus of patients. It measures edema, rings and strictures and other visible markers of disease often associated with symptoms. Today’s data demonstrated improvement in two key outcomes with EP-104GI in the treatment of EoE: first, that a full injection protocol of 20 injections resulted in more pronounced improvement than a protocol with fewer injections and less coverage area within the esophagus; second, with the higher number of injections, a consistent response in both the inflammatory and fibrotic sub scores of EREFS was observed,” said Dr. James A. Helliwell, Chief Executive Officer of Eupraxia. “This EREFS data being reported at DDW is consistent with the improvements we have seen in EoE symptoms and tissue health (EoEHSS) and suggests improvement in inflammation, fibrosis and the associated narrowing of the esophagus.”

Eurpraxia announced on Friday, May 1, the appointment of Dr. Jeymi Tambiah as Chief Medical Officer (CMO) as well as the retirement of Dr. Mark Kowalski, Eupraxia’s current CMO. Dr. Jeymi Tambiah (MB ChB, FRCS, MS, FAPCR, FFPM), is a Board Certified Cardiothoracic Surgeon physician scientist who practiced at Guys and St Thomas’ Hospitals prior to entering the biopharmaceutical industry in 2008. Dr. Tambiah brings over 18 years of experience in clinical development, medical and regulatory strategy, and product commercialization across pharmaceutical and biotechnology organizations.

Eupraxia recently co-hosted a Tribe Public www.TribePublic.com, CEO Presentation & Q&A Webinar event, Wednesday, April 1 titled “Turning EOE Into a Once-a-Year Appointment.” The event featured James A. Helliwell, M.D., Co‑founder and CEO of Eupraxia Pharmaceuticals (NASDAQ: EPRX), who discusses the company’s precision drug‑delivery platform, its approach to Eosinophilic Esophagitis (EoE), and broader pipeline priorities, followed by a focused 5–10 minute Q&A. You may watch it now at this Youtube link.

Modular Medical (MODD, $4.79)

• Modular Medical, Inc. (NASDAQ:MODD), a leader in innovative, patient-centric insulin delivery, saw (May 1) CEO Jeb Besser join Tribe Public’s members to unpack a simple question with big implications: what happens when an “almost‑pumper” market finally meets an FDA‑cleared device built for the rest of us, not just the superusers? Tribe Public hosted its CEO Presentation and Q&A Webinar, “From FDA Wins to Scaling Manufacturing – What Investors Should Watch,” on Friday, May 1, 2026, at 8:00 a.m. PT / 11:00 a.m. ET. In keeping with Tribe’s reputation for efficient programming, the session ran approximately 30 minutes, pairing a focused prepared talk with a 5–10 minute live Q&A segment that allowed investors to drill into timelines, capital needs, and commercial strategy. Besser’s formal remarks were framed under the title “From FDA Wins to Scaling Manufacturing – What Investors Should Watch,” setting the tone for a discussion that sat at the intersection of regulation, innovation, and recurring‑revenue hardware. By registering, attendees also joined Tribe Public’s membership base, ensuring they will receive future invitations to CEO briefings, sector spotlights, and investor wish‑list events.
• Modular Medical announced (APRIL 19) the pricing of a registered direct offering consisting of 750,000 shares of the Company’s common stock at an offering price of $4.50 per share. The gross proceeds to the Company from the Offering are estimated to be approximately $3.4 million before deducting placement agent fees and other offering expenses. The Offering is expected to close on or about April 21, 2026, subject to the satisfaction of customary closing conditions.
• Modular Medical’s latest regulatory milestone upgrades the narrative: the company has now (April 9) secured FDA 510(k) clearance for its Pivot tubeless insulin patch pump, moving from “launch‑ready” to “launch‑approved” in the heart of the fast‑growing diabesity market. The FDA has cleared Modular Medical’s Pivot patch pump as a tubeless, removable insulin delivery system, formally validating the device’s design and performance for commercial use in U.S. adults living with diabetes. The clearance converts what had been a Q1 2026 launch “subject to FDA response” into a tangible commercial pathway, giving the company permission to sell into an insulin pump market that has been estimated at roughly 8 billion dollars globally. Pivot is engineered as a simplified, two‑part patch pump with a 3‑milliliter removable reservoir, no need for battery recharging, and the ability to bolus without a dedicated controller, aiming squarely at patients who have stayed on multiple daily injections because traditional pumps felt too complex, cumbersome, or costly. By clearing Pivot, the FDA is effectively endorsing Modular Medical’s attempt to make advanced insulin delivery feel less like adopting a gadget and more like upgrading a daily habit.

The InterGroup Corporation (INTG, $37.41, +3.10%)

• The InterGroup Corporation (NASDAQ: INTG) announced financial (May 11) results for the fiscal third quarter ended March 31, 2026. InterGroup is a diversified holding company with interests in hospitality (through its majority‑owned subsidiary Portsmouth Square, Inc.), real estate operations, and investment transactions. The discussion below is derived from the Company’s Quarterly Report on Form 10‑Q for the quarter ended March 31, 2026. Third Quarter Fiscal 2026 Highlights (Three Months Ended March 31, 2026 vs. 2025) are as follows:
  • Total revenues increased to $20.372 million from $16.824 million (+21%).
  • Income from operations increased to $4.260 million from $2.350 million (+81%).
  • GAAP net income was $0.595 million, compared to a GAAP net loss of $0.750 million in the prior‑year quarter.
  • Net income attributable to InterGroup was $0.457 million, or $0.21 per diluted share, compared to a net loss attributable to InterGroup of $0.578 million, or $0.27 per share, in the prior‑year quarter.
  • Hotel revenues increased to $16.497 million from $12.210 million (+35%). For additional context, Hotel revenues for the quarter ended March 31, 2026 exceeded the comparable pre‑pandemic quarter ended March 31, 2019 by approximately $1.028 million.
  • Real estate revenues were $3.875 million compared to $4.614 million in the prior‑year quarter (‑16%).
  • Net loss from investment transactions was $(0.342) million compared to $(1.379) million in the prior‑year quarter.

Volato Group, Inc. (SOAR, +29.29%) & M2i Global, Inc. (MTWO, +2.09%)

• M2i Global, Inc., a company specializing in the development and execution of a complete global value supply chain for critical minerals, under Definitive Agreement to merge with Volato Group, Inc. (“Volato”) (NYSE American: SOAR), a technology-driven company, announced (June 1) the execution of a Letter of Intent (“LOI”) with Aurica Tokenization, Inc. (“Aurica”), a Nevada-domiciled commodity-tokenization company focused on physically-backed gold and strategic-mineral tokens.
• Volato Group, Inc. (NYSE American: SOAR) announced (May 18) that its pro-forma cash balance was $5.5 million at March 31, 2026. This pro-forma cash balance equates to $0.14 cash per share. The pro-forma calculation includes cash raised in April from its now completed ATM Prospectus Supplement filed on March 30, 2026.
• Volato Group, Inc. (NYSE American: SOAR) recently announced voting results indicate that the shareholders have approved the previously announced merger with M2i Global, Inc. (“M2i Global”)(OTCQB: MTWO) with 99% of the shares of common stock present or represented by valid proxy at the special meeting voting in favor of the merger. This marks a significant milestone toward closing the transaction and advancing Volato’s strategic expansion into the critical minerals sector. The number of shares of common stock present or represented by valid proxy at the special meeting was 15.1 million, representing approximately 40% of the total number of shares of common stock entitled to vote. Management believes that the approval reflects strong shareholder alignment with the Company’s strategic direction and long-term growth plans.

Nokia (NOK, $16.85, +3.69%)

• Nokia has quietly stitched together a new chapter in its comeback story—one that runs from American living rooms to Pentagon test ranges, and now straight through NVIDIA’s (NVDA) data centers. With NVIDIA’s billion‑dollar vote of confidence in the fall and another blockbuster NVIDIA earnings report due today, the old handset icon is suddenly speaking fluent AI.
• Nokia announced (May 21) the launch of its AI Networking Innovation Lab, a new center designed to drive co-innovation with AI and cloud partners and accelerate the development of next-generation networking technologies for artificial intelligence (AI) infrastructure. Located within Nokia’s Sunnyvale, California facility, the lab serves as an innovation hub where Nokia will work across advanced AI networking technologies, architectures and ecosystems with a variety of partners to help shape the future of data center networking. AI workloads are fundamentally changing how data center networks must operate. The performance, scale, and precision required to support large-scale AI training and distributed, real-time inference place unprecedented demands on networking infrastructure. To address these challenges, Nokia is adopting a new approach to how technologies are integrated, tested, and deployed from the ground up for the AI era.

NVIDIA (NVDA, $222.82)

This year, one of the marquee attractions isn’t on the show floor at Computex 2026 at all but on stage at the Taipei Music Center, where Nvidia (NVDA) chief executive Jensen Huang is scheduled to deliver a keynote as part of an adjacent GTC Taipei event. The company bills it as a tour of “AI factories and scaling infrastructure,” the kind of phrasing that makes data centers sound less like buildings and more like money‑printing machines. The semantics matter. “AI factory” implies a production system that converts capex into recurring intelligence, a comforting metaphor for investors hunting for durable free‑cash‑flow stories in a market that has already repriced anything with “GPU” in its slide deck. With Huang’s appearances now treated by some funds as quasi‑macro events, the Computex keynote doubles as a sentiment check on whether the AI infrastructure cycle can remain in “up and to the right” territory for another year.

Tigress Financial raised their price target to $425 on May 27 and maintained their ‘Strong Buy’ Rating.

Nvidia’s First Quarter Fiscal 2027 earnings report crossed the tape Wednesday, May 20, and the immediate takeaway is that the AI engine is still running at full throttle, even if Wall Street was already leaning hard on the accelerator. The story today is less about whether Nvidia is growing and more about just how far into “infrastructure of AI” territory it has now ventured.

McDonald’s (MCD, $276.36, +.77%)

• Morgan Stanley (April 21) has adjusted its price target on McDonald’s (MCD) to $334, maintaining an Equal Weight stance on the stock. The firm’s analyst highlighted consumer strength heading into first-quarter results, noting that earnings quality will likely vary across the restaurant and food distribution landscape . While some operators may face headwinds, the underlying consumer backdrop remains robust, which could support McDonald’s performance as one of the industry’s quality players positioned to navigate the current environment .

Tesla (TSLA, $423.74, +1.89%)

Reuters reported that new registrations of Tesla (TSLA), opens new tab cars rose across several ​European markets in May, continuing a recovery in the U.S. electric vehicle maker’s European sales.

Serina Therapeutics (NYSE: SER, $1.76)

Serina Therapeutics, Inc. (“Serina” or the “Company”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, reported (May 14) its financial results for the first quarter ended March 31, 2026, along with key business updates. The company highlighted the follow: Phase 1b Registrational Clinical Study of SER-252 Underway in Advanced Parkinson’s Disease; TFL data from the SAD study arm targeted for first half of 2027 & Closed $21.2 million private placement financing to support continued advancement of SER-252. “With our Phase 1b registrational study of SER-252 now underway and a strengthened balance sheet, Serina is entering an important execution phase as we work toward our first clinical data in patients with advanced Parkinson’s disease,” said Steve Ledger, Chief Executive Officer of Serina. “SER-252 represents the first clinical validation of our POZ Platform™, which is designed to optimize well-understood therapeutics by improving pharmacokinetics, tolerability and dosing profiles. We believe this approach has the potential to unlock meaningful value across multiple modalities, and we are building a pipeline and partnership strategy to fully leverage the breadth of the platform.”

BuzzFeed, Inc. (BZFD, $1.59)

BuzzFeed, Inc. (“BuzzFeed” or the “Company”) (Nasdaq: BZFD) today announced the closing of its previously announced transaction with Allen Family Digital, LLC, an affiliate of Byron Allen’s Family Office, under which Allen Family Digital, LLC acquired approximately 51% of the Company’s outstanding shares. Byron Allen has assumed the role of Chairman and Chief Executive Officer, and Jonah Peretti has transitioned to his newly created role as President of BuzzFeed AI. Under the terms of the agreement, Allen Family Digital acquired 40 million shares of BuzzFeed, Inc. common stock at a price of $3.00 per share, representing a total transaction value of $120 million for a total purchase price of $120 million. The transaction was funded with $20 million in cash at closing and a $100 million promissory note due five years from closing, accruing interest at 5% annually. BuzzFeed has used $12.5 million of the cash proceeds from the transaction to pay down existing indebtedness, materially strengthening the Company’s balance sheet and enhancing financial flexibility to support future growth initiatives. “Jonah is a great visionary and has done a phenomenal job. BuzzFeed and HuffPost have become two iconic global digital media brands with powerful audience reach and strong cultural importance,” said Byron Allen, Chairman and CEO of BuzzFeed. “Our vision is to build on the iconic foundation of BuzzFeed and HuffPost by expanding into free-streaming video, audio and user-generated content. As of this moment, with the power of AI, BuzzFeed is officially chasing YouTube to become another premier free-streaming video service.”

FMC Corporation (NYSE: FMC, $13.13)

FMC Corporation (NYSE: FMC) announced (May 26) that Andrew Sandifer, FMC executive vice president and chief financial officer, will speak at the 16th Annual Wells Fargo Industrials & Materials Conference on June 9, 2026, at 2:15 p.m. Central Time. A live webcast will be available at www.fmc.com/investors.

FMC Corporation (NYSE:FMC) reported (April 29) first quarter 2026 results above guidance with Adjusted EBITDA above high end of range, reaffirms full-year outlook. Their first quarter 2026 revenue of $759 million, down 4 percent versus first quarter 2025. First quarter 2026 revenue, excluding India, was $762 million, down 4 percent versus first quarter 2025, which included India. On a GAAP basis, the company reported a loss of $2.25 per diluted share in the first quarter, a decrease of $2.13 versus first quarter 2025. First quarter adjusted loss per diluted share of $0.23 was down 41 cents versus first quarter 2025. FMC Corporation also announced today that its board of directors declared a regular quarterly dividend of 8 cents per share (roughly 2.26%), payable on July 16, 2026, to shareholders of record as of the close of business on June 30, 2026.

GeoVax Labs, Inc. (GOVX, $2.10)

GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines, announced (May 26) a strategic prioritization of its development portfolio to concentrate resources on its lead programs, GEO-MVA and Gedeptin(R), reflecting increasing clinical, regulatory, and market alignment across these programs. As part of this decision, the Company has elected to discontinue active development activities related to its GEO-CM04S1 COVID-19 vaccine candidate. This decision was not related to any safety concerns with the vaccine but reflects the continued evolution and contraction of the global COVID-19 vaccine market, and GeoVax’s focus on programs with clearer regulatory pathways, stronger demand visibility, and more immediate commercialization potential. GeoVax emphasized that portfolio prioritization is a standard and essential practice within the biotechnology industry, enabling companies to align resources with the highest-value opportunities as market conditions and scientific landscapes evolve.

Tribe Public’s CEO Presentation and Q&A Webinar Event titled “Ebola, Marburg, Hantavirus, Mpox and Beyond: Building a Resilient Infectious Disease Portfolio Preparedness Strategy” was held Thursday, May 28, 2026. David Dodd, Chairman and Chief Executive Officer of GeoVax Labs, Inc. (NASDAQ: GOVX) delivered a presentation titled “Ebola, Marburg, Hantavirus, Mpox and Beyond: Building a Resilient Infectious Disease Portfolio Preparedness Strategy” and was available for a Q&A session.

The Sources